Experimental Pathogenesis & Therapy of Ocular Adenovirus
Experimental Pathogenesis & Therapy of Ocular Adenovirus
批准号:
6778175
负责人:
Y JEROLD GORDON
金额:
$43.24万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-09-01 至 2007-06-30
关键词:
2&apos3&apos dideoxycytidineAdenoviridaeDNA directed DNA polymeraseantiviral agentscytosine analogdisease /disorder modeldrug resistancedrug screening /evaluationeye disorder chemotherapyeye infectionseye pharmacologygene mutationhuman tissuelaboratory rabbitmolecular pathologynonhuman therapy evaluationtissue /cell culturetopical drug applicationvirus diseasesvirus replication
中文摘要
描述(由申请人提供):在21世纪世纪,腺病毒(Ad)眼部感染仍然是一个重要的世界性问题,对此没有抗病毒治疗选择。一个长期目标是开发有效的局部抗病毒药物来治疗腺病毒眼部感染。在这一竞争性更新中,我们将在体外和兔眼模型中评估几种有前途的抗病毒药物(ddC,NCT,CPE-C),并确定临床开发的最佳候选药物。将讨论候选抗病毒药物出现耐药性的问题,并在确定其各自的抑制作用分子机制后评估抗病毒药物之间临床显著交叉耐药性的可能性。最后,我们将描述局部先天免疫的作用,最初保护眼睛免受腺病毒感染。具体来说,我们将评估防御素样化合物的作用,包括α和β防御素,防御素样趋化因子(CXCL 10和CXCL 11),和cathelicidins。这些发病机制研究的结果将推进我们对腺病毒如何克服宿主防御以成功建立眼部感染的了解。总之,有效的抗病毒治疗的发展应该减轻病人的痛苦,限制流行病,并减少缺勤造成的经济,教育和其他社会损失。此外,更好地了解抗病毒耐药性和先天免疫宿主防御将使我们能够优化针对这种重要眼部病原体的治疗选择。
英文摘要
DESCRIPTION (provided by applicant): In the 21st century, adenovirus (Ad) ocular infections remain a significant worldwide problem for which there are no antiviral treatment options. One long term objective is to develop an effective topical antiviral to treat adenoviral ocular infections. In this competing renewal, we will evaluate several promising antivirals (ddC, NCT, CPE-C) in vitro and in our rabbit ocular model and determine the best candidate for clinical development. The issue of emerging resistance to candidate antivirals will be addressed and the possibility of clinically-significant cross resistance among antivirals will be assessed following the determination of their respective molecular mechanisn(s) of inhibitory action. Finally, we will characterize the role of local innate immunity that initially protects the eye from infection by adenovirus. Specifically, we will evaluate the role of defensin-like compounds including alpha and beta defensins, defensin-like chemokines (CXCL 10 and CXCL 11), and cathelicidins. The results of these pathogenesis studies will advance our knowledge of how adenovirus overcomes host defenses to successfully establish eye infections. In summary, the development of an effective antiviral treatment should lessen patient misery, limit epidemics, and reduce economic, educational and other societal losses from absenteeism. Furthermore, a better understanding of antiviral resistance and the innate immune host defenses will enable us to optimize our therapeutic options against this significant ocular pathogen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:6384613
-
项目类别:
-
资助金额:$31.47万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:3265441
-
项目类别:
-
资助金额:$21.08万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
Experimental Pathogenesis & Therapy of Ocular Adenovirus
-
批准号:6681766
-
项目类别:
-
资助金额:$42.83万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2019730
-
项目类别:
-
资助金额:$30.18万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2162111
-
项目类别:
-
资助金额:$27.39万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
Experimental Pathogenesis & Therapy of Ocular Adenovirus
-
批准号:7087716
-
项目类别:
-
资助金额:$43.35万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2888343
-
项目类别:
-
资助金额:$30.15万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:3265440
-
项目类别:
-
资助金额:$25.09万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:3265439
-
项目类别:
-
资助金额:$23.4万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2701375
-
项目类别:
-
资助金额:$29.51万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:6179895
-
项目类别:
-
资助金额:$30.8万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
Experimental Pathogenesis & Therapy of Ocular Adenovirus
-
批准号:6908885
-
项目类别:
-
资助金额:$43.81万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2162110
-
项目类别:
-
资助金额:$26.53万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
EXPERIMENTAL PATHOGENESIS & THERAPY OF OCULAR ADENOVIRUS
-
批准号:2162112
-
项目类别:
-
资助金额:$28.23万
-
财政年份:1991
-
负责人:Y JEROLD GORDON
-
依托单位:
CELL BIOLOGY OF THE OCULAR SURFACE DISEASES
-
批准号:2159798
-
项目类别:
-
资助金额:$23.15万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
HSV 1 LATENCY--IMMUNIZATION AND RECURRENT OCULAR DISEASE
-
批准号:3260142
-
项目类别:
-
资助金额:$12.47万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
HSV 1 LATENCY--IMMUNIZATION AND RECURRENT OCULAR DISEASE
-
批准号:3260144
-
项目类别:
-
资助金额:$19.62万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
HSV 1 LATENCY--IMMUNIZATION AND RECURRENT OCULAR DISEASE
-
批准号:3260141
-
项目类别:
-
资助金额:$12.98万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
HSV 1 LATENCY--IMMUNIZATION AND RECURRENT OCULAR DISEASE
-
批准号:3260138
-
项目类别:
-
资助金额:$19.14万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
HSV 1 LATENCY--IMMUNIZATION AND RECURRENT OCULAR DISEASE
-
批准号:3260143
-
项目类别:
-
资助金额:$18.25万
-
财政年份:1985
-
负责人:Y JEROLD GORDON
-
依托单位:
国内基金
登录
查看更多内容
晚期妊娠维持和抑制早产中cAMP信号活化PR的作用机制研究
-
批准号:81300507
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2013
-
负责人:陈黎
-
依托单位:
3'-甲氧基葛根素生物合成途径中关键甲基转移酶基因的克隆与功能分析
-
批准号:31300258
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:黎佳
-
依托单位:
3'-UTR单核苷酸多态性影响CYP8B1基因表达致胆囊胆固醇结石形成的机制研究
-
批准号:81370561
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:秦俭
-
依托单位:
异源杂交多倍化鲫鲤特有性状的转录组及后转录组水平变化规律研究
-
批准号:31360514
-
项目类别:地区科学基金项目
-
资助金额:54.0万元
-
批准年份:2013
-
负责人:罗静
-
依托单位:
HIF基因3'UTR区SNP参与胰腺癌HIF-1α表达调控的分子机制及功能研究
-
批准号:81302082
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王秀超
-
依托单位:
鼻咽癌转移相关通路分子的microRNA调控机制及3'UTR区可变剪切的作用研究
-
批准号:81372886
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:买世娟
-
依托单位:
小鼠精原干细胞中APA位点研究及3'UTR使用频率数据库构建
-
批准号:31301085
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2013
-
负责人:熊远妍
-
依托单位: